Fascia Iliaca Compartment Block For Analgesia After Total Hip Arthroplasty
Condition: Pain Disorder; Sensory Deficit
MeSH terms: Somatoform Disorders
Study type: Interventional

Summary: 
      Introduction Fascia Iliaca compartment block (FICB) is commonly used to treat pain in
      patients after total hip arthroplasty (THA) despite the lack of RCTs to evaluate the efficacy
      of FICB for this indication. Therefore the objective of this study was to assess the
      analgesic benefit of FICB for post-operative pain management in THA.

      Methods After IRB approval and informed consent, patients having THA at our center in the
      period 2010-2011 were recruited. Eligible patients were adults, ASA physical status I-III,
      and BMI <30) with no contraindication to study procedures. In the PACU, all patients received
      morphine sulfate IVPCA; patients reporting pain > 3 on the NRS-11 despite IVPCA were
      randomized by the method of sealed envelopes to receive US guided injections of 30ml 0.5%
      ropivacaine (FICB) or 30ml 0.9% NaCl (sham block, SB) beneath the fascia iliaca.

      The primary outcome variable was opioid analgesic consumption during the first 24 h
      postoperatively. Secondary outcome measures were pain intensity (NRS-11) and extent of
      sensory blockade.
    

Detailed description: 
      Introduction Fascia Iliaca compartment block (FICB) is commonly used to treat pain in
      patients after total hip arthroplasty (THA) despite the lack of RCTs to evaluate the efficacy
      of FICB for this indication. Therefore the objective of this randomized, prospective trial
      was to assess the analgesic benefit of FICB for post-operative pain management in THA. Our
      hypothesis was that FICB would confer an analgesic benefit for patients after THA.

      Methods After IRB approval and informed consent, patients having THA at our center in the
      period 2010-2011 were recruited in the morning of their surgery. Eligible patients were
      adults, ASA physical status I-III, and BMI <30) with no contraindication to study procedures.
      In the PACU, all patients received morphine sulfate IVPCA; patients reporting pain > 3 on the
      NRS-11 despite IVPCA were randomized by the method of sealed envelopes to receive US guided
      injections of 30ml 0.5% ropivacaine (FICB) or 30ml 0.9% NaCl (sham block, SB) beneath the
      fascia iliaca.

      The primary outcome variable was opioid analgesic consumption during the first 24 h
      postoperatively. Secondary outcome measures were pain intensity (NRS-11) and extent of
      sensory blockade.
    

Intervention name(s): Fascia iliaca compartment block; Fascia Iliaca compartment block
Intervention type(s): Procedure; Procedure
Intervention description(s): 30 ml 0.5% ropivacaine, beneath the fascia iliaca; 30 ml 0.9% NaCl (sham block, SB), beneath the fascia iliaca
Other intervention name(s): Ultrasound guided Fascia iliaca compartment block; FICB; Ultrasound guided Fascia iliaca compartment block; FICB
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary purpose: Treatment
Keywords: Fascia Iliaca compartment block, Pain, Sensorial blockade